KR900002802A - 면역억제제로서의 트랜스글루타미나제의 용도 - Google Patents

면역억제제로서의 트랜스글루타미나제의 용도 Download PDF

Info

Publication number
KR900002802A
KR900002802A KR1019890012384A KR890012384A KR900002802A KR 900002802 A KR900002802 A KR 900002802A KR 1019890012384 A KR1019890012384 A KR 1019890012384A KR 890012384 A KR890012384 A KR 890012384A KR 900002802 A KR900002802 A KR 900002802A
Authority
KR
South Korea
Prior art keywords
prepared
use according
transglutaminase
agent
units
Prior art date
Application number
KR1019890012384A
Other languages
English (en)
Other versions
KR0154523B1 (ko
Inventor
스티프 토마스
하임부르거 노르베르트
울리히 쇼를렘머 한스
Original Assignee
필립 스타인, 헤리베르트 버그
베링베르케 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 필립 스타인, 헤리베르트 버그, 베링베르케 아크티엔게젤샤프트 filed Critical 필립 스타인, 헤리베르트 버그
Publication of KR900002802A publication Critical patent/KR900002802A/ko
Application granted granted Critical
Publication of KR0154523B1 publication Critical patent/KR0154523B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • C12N9/1044—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

내용 없음

Description

면역억제제로서의 트랜스글루타미나제의 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (11)

  1. 면역억제제를 제조하는 방법에서의 트랜스글루타미나제의 용도.
  2. 제 1 항에 있어서, 트랜스글루타미나제가 팩터 XⅢ인 용도.
  3. 제 1 항에 있어서, 이식거부반응 및 태반/트로포블라스트 장애 및 이식조직 대 숙주반응의 치료 및 예방제가 제조되는 용도.
  4. 제 1 항에 있어서, 자가면역질환의 치료제가 제조되는 용도.
  5. 제 1 항에 있어서, 산소 래디칼의 형성 증가와 관련된 병리학적 진행의 치료제가 제조되는 용도.
  6. 제 1 항에 있어서, 급성 재환류도중 및 후 조직 손상의 치료 및 예방제가 제조되는 용도.
  7. 제 1 항에 있어서, 국소용 제제가 제조되는 용도.
  8. 제 1 항에 있어서, 단핵구/대식 세포계의 억제제가 제조되는 용도.
  9. 제 1 항에 있어서, 용량당(75kg체중) 트랜스 글루타미나제 52.5 내지 225,000유니트를 함유하는 제제가 제조되는 용도.
  10. 트랜스글루타미나제 및 플라스미노겐 활성제 억제제, 바람직하게는 PAI-2를 함유하는 조성물
  11. 제10항에 있어서, 용량당(75kg체중) 트랜스 글루타미나제 52.5 내지 225,000유니트와 용량당 플라스미노겐 활성제 억제제 525 내지 225,000유니트를 함유하는 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890012384A 1988-08-31 1989-08-30 면역억제제로서의 트랜스글루타미나제의 용도 KR0154523B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3829524A DE3829524A1 (de) 1988-08-31 1988-08-31 Verwendung von transglutaminasen als immunsuppressiva
DEP3829524.5 1988-08-31

Publications (2)

Publication Number Publication Date
KR900002802A true KR900002802A (ko) 1990-03-23
KR0154523B1 KR0154523B1 (ko) 1998-11-16

Family

ID=6361974

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890012384A KR0154523B1 (ko) 1988-08-31 1989-08-30 면역억제제로서의 트랜스글루타미나제의 용도

Country Status (11)

Country Link
US (2) US5464615A (ko)
EP (1) EP0358995B1 (ko)
JP (1) JP2831045B2 (ko)
KR (1) KR0154523B1 (ko)
AT (1) ATE94762T1 (ko)
AU (1) AU627489B2 (ko)
CA (1) CA1338776C (ko)
DE (2) DE3829524A1 (ko)
DK (1) DK174512B1 (ko)
ES (1) ES2059658T3 (ko)
PT (1) PT91583B (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3829524A1 (de) * 1988-08-31 1990-03-01 Behringwerke Ag Verwendung von transglutaminasen als immunsuppressiva
DE3829523A1 (de) * 1988-08-31 1990-03-01 Behringwerke Ag Verwendung von plasminogen-aktivator-inhibitor (pai-2) zur immunsuppression
JPH03240738A (ja) * 1990-02-20 1991-10-28 Hoechst Japan Ltd 糖尿病性壊疽治療剤
JP3550685B2 (ja) * 1992-04-21 2004-08-04 味の素株式会社 創傷治療剤
DK0669834T3 (da) * 1992-11-12 2000-04-17 Zymogenetics Inc Anvendelse af topisk påført faktor Xlll til inhibering af blødning
AU674061B2 (en) * 1993-03-30 1996-12-05 Hoechst Japan Limited Factor XIII for treatment of skin wounds
DE19630557C2 (de) * 1996-07-18 1998-07-02 Schuppan Detlef Priv Doz Dr Dr Verfahren zum Nachweis von Antikörpern aus Körperflüssigkeiten durch eine Immunreaktion mit Gewebe-Transglutaminase (tTG) sowie die Verwendung von tTG in Diagnose und Therapie
WO1998051333A1 (en) * 1997-05-14 1998-11-19 Zymogenetics, Inc. Use of factor xiii for the manufacture of a medicament for the treatment of reperfusion injury and mucosal damage
EP1201136A1 (en) * 2000-10-31 2002-05-02 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Food grade transglutaminase inhibitor and uses thereof
DE60234057D1 (de) 2001-07-25 2009-11-26 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
CN103259027A (zh) 2005-04-28 2013-08-21 普罗透斯数字保健公司 药物信息系统
KR20090071598A (ko) 2006-09-18 2009-07-01 랩터 파마슈티컬 인코포레이티드 수용체 결합 단백질(ｒａｐ)-접합체 투여에 의한 간 질환의 치료
TWI556839B (zh) 2009-05-06 2016-11-11 研究室護膚股份有限公司 包含活性劑－磷酸鈣粒子複合物之皮膚遞送組成物及其使用方法
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
WO2017009136A1 (en) 2015-07-15 2017-01-19 Novo Nordisk Health Care Ag Factor xiii for the treatment of interstitial cystitis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT359652B (de) * 1979-02-15 1980-11-25 Immuno Ag Verfahren zur herstellung eines gewebekleb- stoffes
JPS56135418A (en) * 1980-03-27 1981-10-22 Green Cross Corp:The Heat treatment of aqueous solution containing 8 factor of coagulation of blood derived from human
DE3360633D1 (en) * 1982-02-12 1985-10-03 Unitika Ltd Anti-cancer device
US4923807A (en) * 1984-05-18 1990-05-08 New England Medical Center Hospitals Inc. Arg-Serpin human plasminogen activator inhibitor designated PAI-2
EP0278667B1 (en) * 1987-02-09 1994-07-20 Mycogen Plant Science, Inc. Hybrid RNA virus
JPS63196520A (ja) * 1987-02-09 1988-08-15 Hoechst Japan Kk 潰瘍性大腸炎治療剤
US5013719A (en) * 1988-05-13 1991-05-07 Merrell Dow Pharmaceuticals Inc. Method of effecting immunosuppression
DE3829524A1 (de) * 1988-08-31 1990-03-01 Behringwerke Ag Verwendung von transglutaminasen als immunsuppressiva

Also Published As

Publication number Publication date
ATE94762T1 (de) 1993-10-15
US5695753A (en) 1997-12-09
ES2059658T3 (es) 1994-11-16
DK427989D0 (da) 1989-08-30
EP0358995A2 (de) 1990-03-21
EP0358995B1 (de) 1993-09-22
AU4090489A (en) 1990-03-08
JPH02108631A (ja) 1990-04-20
JP2831045B2 (ja) 1998-12-02
KR0154523B1 (ko) 1998-11-16
DE3829524A1 (de) 1990-03-01
CA1338776C (en) 1996-12-10
AU627489B2 (en) 1992-08-27
DE58905671D1 (de) 1993-10-28
PT91583A (pt) 1990-03-30
PT91583B (pt) 1995-05-31
EP0358995A3 (en) 1990-08-16
DK174512B1 (da) 2003-05-05
US5464615A (en) 1995-11-07
DK427989A (da) 1990-03-01

Similar Documents

Publication Publication Date Title
KR900002802A (ko) 면역억제제로서의 트랜스글루타미나제의 용도
AU3275689A (en) Process for stabilizing human albumin solutions and the solution obtained
HUT60630A (en) Process or producing peroral pharmaceutical compositions suitable for treating internal diseases of inflammatory nature
ES2166783T3 (es) Factor viii activado utilizado como agente terapeutico y metodo para el tratamiento de la deficiencia de factor viii.
DE3684409D1 (de) Verwendung von gamma-linolensaeure und verwandten verbindungen zur herstellung eubnes arzneimittels zur behandlung von endometriose.
GR3019514T3 (en) Pharmaceutical preparation for the treatment of prolonged coagulation time
EP0355811A3 (en) Thrombus control agent
ES435273A1 (es) Un procedimiento de preparacion de n-(1-bencil-pirrolidi- nil-2-alcohil) -benzamidas sustituidas.
DE59600683D1 (de) Verwendung von Trospiumchlorid zur Herstellung eines Arzneimittels zur Behandlung von Blasenkrankheiten
DE69521536D1 (de) Zusammensetzungen die G-CSF und ein TNF-Bindungsprotein enthalten
KR900002791A (ko) 면역억제를 위한 플라스미노겐 활성인자 억제 인자(pai-2)의 용도
YU13599A (sh) Primena farmaceutske kompozicije za dobijanje leka u obliku gela
KR880009661A (ko) 궤양성 대장염치료를 위한 사람의 혈액응고인자 xiii의 용도
KR960704933A (ko) 난치성 동통에 대한 진통제 및 완화제로서의 릴렉신의 용도
KR890003373A (ko) 수면장애 및 우울증 치료에 화합물의 이용
MX9700967A (es) Uso terapeutico de acetazolamida para el tratamiento de edema cerebral.
KR870010871A (ko) 재조합 인체 알파 인터페론에 의한 기저세포 암종의 병소내적 치료방법
KR900017599A (ko) 종양 치료용 약학 조성물
CA2036592A1 (en) Therapeutic agent for diabetic gangrene
SU1113093A1 (ru) Способ лечени остеомиелита
SU628904A1 (ru) Способ обезболивани
KR890015744A (ko) 과요산헐증치료제
KR920009403A (ko) 수면장해 치료용 이미다조벤조디아제핀
KR890001567A (ko) 디플루니살 및 트로메타민-함유 조성물
RU94005179A (ru) Средство для лечения больных очаговой склеродермией

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
N231 Notification of change of applicant
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20100708

Year of fee payment: 13

LAPS Lapse due to unpaid annual fee